Literature DB >> 28684006

Evolution in the Surgical Care of Patients With Non-Small Cell Lung Cancer in the Mid-South Quality of Surgical Resection Cohort.

Nicholas R Faris1, Matthew P Smeltzer2, Fujin Lu1, Carrie L Fehnel1, Nibedita Chakraborty1, Cheryl L Houston-Harris1, E Todd Robbins3, Raymond S Signore3, Laura M McHugh3, Bradley A Wolf4, Lynn Wiggins5, Paul Levy6, Vishal Sachdev7, Raymond U Osarogiagbon8.   

Abstract

Surgery is the most important curative treatment modality for patients with early-stage non-small cell lung cancer (NSCLC). We examined the pattern of surgical resection for NSCLC in a high incidence and mortality region of the United States over a 10-year period (2004-2013) in the context of a regional surgical quality improvement initiative. We abstracted patient-level data on all resections at 11 hospitals in 4 contiguous Dartmouth Hospital Referral Regions in North Mississippi, East Arkansas, and West Tennessee. Surgical quality measures focused on intraoperative practice, with emphasis on pathologic nodal staging. We used descriptive statistics and trend analyses to assess changes in practice over time. To measure the effect of an ongoing regional quality improvement intervention with a lymph node specimen collection kit, we used period effect analysis to compare trends between the preintervention and postintervention periods. Of 2566 patients, 18% had no preoperative biopsy, only 15% had a preoperative invasive staging test, and 11% underwent mediastinoscopy. The rate of resections with no mediastinal lymph nodes examined decreased from 48%-32% (P < 0.0001), whereas the rate of resections examining 3 or more mediastinal stations increased from 5%-49% (P < 0.0001). There was a significant period effect in the increase in the number of N1, mediastinal, and total lymph nodes examined (all P < 0.0001). A quality improvement intervention including a lymph node specimen collection kit shows early signs of having a significant positive effect on pathologic nodal examination in this population-based cohort. However, gaps in surgical quality remain.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  lung cancer; lymph nodes; mediastinum; surgery

Mesh:

Year:  2016        PMID: 28684006      PMCID: PMC5502738          DOI: 10.1053/j.semtcvs.2016.10.001

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  24 in total

1.  Use of a surgical specimen-collection kit to improve mediastinal lymph-node examination of resectable lung cancer.

Authors:  Raymond U Osarogiagbon; Laura E Miller; Robert A Ramirez; Christopher G Wang; Thomas F O'Brien; Xinhua Yu; Alim Khandekar; Glenn P Schoettle; Samuel G Robbins; Edward T Robbins; Jeffrey B Gibson
Journal:  J Thorac Oncol       Date:  2012-08       Impact factor: 15.609

2.  Patterns of surgical care of lung cancer patients.

Authors:  Alex G Little; Valerie W Rusch; James A Bonner; Laurie E Gaspar; Mark R Green; W Richard Webb; Andrew K Stewart
Journal:  Ann Thorac Surg       Date:  2005-12       Impact factor: 4.330

3.  Mediastinal lymph node examination and survival in resected early-stage non-small-cell lung cancer in the surveillance, epidemiology, and end results database.

Authors:  Raymond U Osarogiagbon; Xinhua Yu
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

4.  Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer.

Authors:  Michelle S Ludwig; Michael Goodman; Daniel L Miller; Peter A S Johnstone
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

5.  Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients.

Authors:  Joachim Pfannschmidt; Thomas Muley; Heinrich Bülzebruck; Hans Hoffmann; Hendrik Dienemann
Journal:  Lung Cancer       Date:  2006-11-22       Impact factor: 5.705

Review 6.  The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer.

Authors:  Hisao Asamura; Kari Chansky; John Crowley; Peter Goldstraw; Valerie W Rusch; Johan F Vansteenkiste; Hirokazu Watanabe; Yi-Long Wu; Marcin Zielinski; David Ball; Ramon Rami-Porta
Journal:  J Thorac Oncol       Date:  2015-12       Impact factor: 15.609

7.  Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base.

Authors:  Raymond U Osarogiagbon; Chun Chieh Lin; Matthew P Smeltzer; Ahmedin Jemal
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

Review 8.  Lung Cancer Statistics.

Authors:  Lindsey A Torre; Rebecca L Siegel; Ahmedin Jemal
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

9.  Multi-modality mediastinal staging for lung cancer among medicare beneficiaries.

Authors:  Farhood Farjah; David R Flum; Scott D Ramsey; Patrick J Heagerty; Rebecca Gaston Symons; Douglas E Wood
Journal:  J Thorac Oncol       Date:  2009-03       Impact factor: 15.609

10.  Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors.

Authors:  Daniel J Boffa; Mark S Allen; Joshua D Grab; Henning A Gaissert; David H Harpole; Cameron D Wright
Journal:  J Thorac Cardiovasc Surg       Date:  2007-12-21       Impact factor: 5.209

View more
  8 in total

1.  Effectiveness of Implemented Interventions on Pathologic Nodal Staging of Non-Small Cell Lung Cancer.

Authors:  Meredith A Ray; Nicholas R Faris; Matthew P Smeltzer; Carrie Fehnel; Cheryl Houston-Harris; Paul Levy; Lynn Wiggins; Vishal Sachdev; Todd Robbins; David Spencer; Raymond U Osarogiagbon
Journal:  Ann Thorac Surg       Date:  2018-03-11       Impact factor: 4.330

2.  Survival Before and After Direct Surgical Quality Feedback in a Population-Based Lung Cancer Cohort.

Authors:  Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Carrie Fehnel; Cheryl Houston-Harris; Philip Ojeabulu; Olawale Akinbobola; Yu-Sheng Lee; Meghan Meadows; R Samuel Signore; Lynn Wiggins; David Talton; Edmond Owen; Lawrence E Deese; Richard Eubanks; Bradley A Wolf; Paul Levy; E Todd Robbins; Raymond U Osarogiagbon
Journal:  Ann Thorac Surg       Date:  2018-12-27       Impact factor: 4.330

3.  Survival After Mediastinal Node Dissection, Systematic Sampling, or Neither for Early Stage NSCLC.

Authors:  Meredith A Ray; Matthew P Smeltzer; Nicholas R Faris; Raymond U Osarogiagbon
Journal:  J Thorac Oncol       Date:  2020-06-20       Impact factor: 15.609

4.  Suppression of Circular RNA Hsa_circ_0109320 Attenuates Non-Small Cell Lung Cancer Progression via MiR-595/E2F7 Axis.

Authors:  Qiaohong Bai; Li Li; Futao Chen; Jiang Zhu; Lifeng Cao; Yang Yang; Fukuan Zhong
Journal:  Med Sci Monit       Date:  2020-06-08

5.  Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.

Authors:  Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Raymond U Osarogiagbon
Journal:  JAMA Oncol       Date:  2018-01-01       Impact factor: 31.777

6.  Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.

Authors:  Megan E V Caram; Mary K Oerline; Stacie Dusetzina; Lindsey A Herrel; Parth K Modi; Samuel R Kaufman; Ted A Skolarus; Brent K Hollenbeck; Vahakn Shahinian
Journal:  Cancer       Date:  2020-09-14       Impact factor: 6.860

7.  Institutional factors associated with adherence to quality measures for stage I and II non-small cell lung cancer.

Authors:  Rhami Khorfan; David T Cooke; Robert A Meguid; Leah Backhus; Thomas K Varghese; Farhood Farjah; Karl Y Bilimoria; David D Odell
Journal:  J Thorac Cardiovasc Surg       Date:  2020-07-29       Impact factor: 6.439

8.  Left sleeve lobectomy versus left pneumonectomy for the management of patients with non-small cell lung cancer.

Authors:  Liang Wang; YuQuan Pei; ShaoLei Li; ShanYuan Zhang; Yue Yang
Journal:  Thorac Cancer       Date:  2018-01-17       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.